Secukinumab Provides Sustained Improvements in Signs and Symptoms in Active Psoriatic Arthritis Up-to 3 years: Data from FUTURE1 and FUTURE2 studies
Author Type(s)
Faculty
Document Type
Abstract
Publication Date
5-2018
Journal Title
Australasian Journal of Dermatology
Department
Dermatology
Recommended Citation
Nash, P., Gottlieb, A. B., McInnes, I., Mease, P., Delicha, E., Pellet, P., Kajekar, R., & Pricop, L. (2018). Secukinumab Provides Sustained Improvements in Signs and Symptoms in Active Psoriatic Arthritis Up-to 3 years: Data from FUTURE1 and FUTURE2 studies. Australasian Journal of Dermatology, 59 (Suppl. 1), 88. Retrieved from https://touroscholar.touro.edu/nymc_fac_abstracts/378
COinS
